- Recognized for pioneering the world’s first AI-driven organ regeneration platform
- Awarded Grand Prize in the Bio Category

ROKIT Healthcare (KOSDAQ: 376900, CEO Seokhwan You), a global leader in AI-driven hyper-personalized organ regeneration platforms, has been awarded the Grand Prize in the Bio category at the 2025 Korea SME & Mid-sized Enterprise Awards, hosted by the Dong-A Ilbo and jointly sponsored by the Ministry of Science and ICT and the Ministry of SMEs and Startups.

The award recognizes the company’s leadership in shifting the paradigm of chronic disease treatment toward “hyper-personalized regenerative medicine,” as well as the technical excellence of its next-generation organ regeneration solutions that integrate AI and 3D bioprinting.

Founded in 2012, ROKIT Healthcare became the first company in the world to commercialize patient-specific organ regeneration solutions by combining artificial intelligence (AI) with 3D bioprinting technology. Its AI-driven hyper-personalized organ regeneration platform has demonstrated clinical efficacy with an 82.1% cure rate in diabetic foot ulcer treatment using patient-derived regenerative patches, marking a significant milestone in the field of regenerative medicine.

In 2023, the company obtained both U.S. FDA clearance and European CE MDR certification for its skin regeneration platform, successfully clearing key global regulatory hurdles. This enabled early entry into global markets and contributed to substantial revenue growth.

As a result, since its KOSDAQ listing in May, the company has recorded two consecutive quarters of operating profit, and its share price has increased more than sixfold within six months—an exceptional achievement for a technology-specialized biotech firm—demonstrating rapid commercialization and global scalability.

A ROKIT Healthcare spokesperson stated, “As Korea enters a super-aging society, improving the quality of life for rapidly increasing chronic disease patients while reducing societal medical costs is both our mission and responsibility. We will continue expanding our pipeline into global megamarkets—including cartilage regeneration, kidney regeneration, heart regeneration, and anti-aging—to become a global first mover in organ regeneration and meaningfully extend healthy human lifespan.”